Bayer (BAYRY) sells regorafenib as Stivarga, a colon cancer drug in pre-treated patients. On the stock market today, Exelixis toppled 14.4% to close at 18.56. …
Exelixis, Inc. EXEL was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend …
Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an …
This means EXEL has more control over its partnership with Roche and could become a core partner if the new studies work out, which would be big for Exelixis stock. EXEL is also working with Genentech to explore new potential uses for …
Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, these can also lead on the downside when the growth story is over, …
Among them, Exelixis, Inc. (NASDAQ:EXEL) should be at the top of the list. After a 14% fall Wednesday, EXEL stock took another beating Thursday, losing as much as 12% before closing the session down only 8%. Still, if you’re keeping …
On March 7, Merck (MRK) announced that it had entered a collaboration with Eisai for the co-development and co-commercialization of the latter’s oral protein tyrosine kinase inhibitor, Lenvima, as a monotherapy and in combination …